

Carbon Reduction Plan

Supplier name: IPS Pharma

Publication date: 20/04/2026

Commitment to achieving Net Zero

IPS Pharma is committed to achieving Net Zero emissions by 2050.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

IPS Pharma have baselined calendar year 2023 and therefore publishing baseline and current year emission reporting in tandem.

Baseline Year: 2023

Additional Details relating to the Baseline Emissions calculations.

IPS Pharma have engaged a professional carbon accounting and decarbonisation specialist, Auditel, to help accurately report all required emissions based on activity data and achieve verification standard reporting.

IPS Pharma has prepared this interim update to provide transparency on emissions performance for the 2024 reporting period.

The data presented within this section is based on **preliminary and partially estimated activity data** and has not yet undergone full verification in line with the GHG Protocol corporate standard.

A fully validated Carbon Reduction Plan, including confirmed 2024 emissions data and updated reduction targets, will be published within 12 months of this statement.

Where estimates have been used, these are based on:

- extrapolated activity data
- supplier assumptions
- and/or incomplete Scope 3 datasets currently being refined

Baseline year emissions:

EMISSIONS	TOTAL (tCO₂e)
Scope 1	35.01 tCO₂e
Scope 2	36.85 tCO₂e
Scope 3 (Included Sources)	135.55 tCO₂e 3.3 Fuel and Energy related Activities – 23.18 tCO ₂ e 3.4 Upstream Transport & Distribution – 25.93 tCO ₂ e 3.5 Waste – 0.71 tCO ₂ e 3.6 Business Travel – 1.38 tCO ₂ e 3.7 Employee Commuting (inc. WTT) and homeworking – 14.19 tCO ₂ e 3.9 Downstream Transport & Distribution – 70.15 tCO ₂ e Sources included: Upstream Transportation and Distribution, Waste generated in operations, Business Travel, Employee Commuting, Home Working, Downstream Transportation and Distribution
Total Emissions	221.71 tCO₂e

Current Emissions Reporting

Reporting Year: 2024 Estimated (subject to verification)	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	38.03 tCO₂e (est.)
Scope 2	43.50 tCO₂e (est.)
Scope 3 (Included Sources)	150.3 tCO₂e (est.) 3.3 Fuel and Energy related Activities – 25 tCO ₂ e 3.4 Upstream Transport & Distribution – 28 tCO ₂ e 3.5 Waste – 1.0 tCO ₂ e 3.6 Business Travel – 1.80 tCO ₂ e 3.7 Employee Commuting (inc. WTT) and homeworking – 17.5 tCO ₂ e 3.9 Downstream Transport & Distribution – 77 tCO ₂ e

	Sources included: Upstream Transportation and Distribution, Waste generated in operations, Business Travel, Employee Commuting, Home Working, Downstream Transportation and Distribution
Total Emissions	231.1 tCO2e

Emissions reduction targets

IPS Pharma is currently in the process of developing a comprehensive, verifiable decarbonisation strategy, accompanied by short-term and long-term targets. More details will be released in a future report.


We are committed to reaching Net Zero emissions by 2050 per the requirements of this plan. IPS Pharma is developing a science-aligned decarbonisation strategy, which will include:

- near-term emissions reduction targets
- operational efficiency improvements
- and supply chain engagement initiatives

In the interim, IPS Pharma is committed to:

- continuous reduction of Scope 1 and Scope 2 emissions
- active engagement with logistics and distribution partners to reduce Scope 3 emissions

Progress against these targets can be seen in the graph below:



Carbon Reduction Projects

Since the 2023 baseline year, IPS Pharma has made measurable progress in reducing operational emissions. Key developments include:

- Completion of the transition to a **fully electric vehicle (EV) fleet**, significantly reducing emissions associated with company-owned transport

- Continued optimisation of logistics and distribution activities to improve efficiency and reduce indirect emissions
- Ongoing evaluation of renewable energy solutions across operational sites

These actions represent IPS Pharma's commitment to delivering tangible emissions reductions ahead of the publication of a fully verified decarbonisation strategy.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

Vish Patani

Vish Patani – Chief Financial Officer, IPS Pharma

Date: 20/04/2026

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>